Equibles does not estimate personal net worth.
Get an email with a short summary when Maravai Lifesciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get MRVI alertsRajesh "Raj" Asarpota is recorded as CFO at Maravai Lifesciences Holdings, Inc. (MRVI) since June 30, 2025. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed June 25, 2025 that Rajesh "Raj" Asarpota was appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. Rajesh "Raj" Asarpota has spoken on 1 earnings call across 1 company, most recently for Maravai Lifesciences Holdings, Inc. on February 25, 2026. Maravai Lifesciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Maravai Lifesciences Holdings, Inc. includes Bernd Brust (CEO and Board Member), William "Trey" Martin, III (CEO and Board Member), William E. Martin III (CEO) and 7 others.
“Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh "Raj" Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025.”
“Let's turn to the Q4 financial results on slide 10. Revenue for the quarter was $49.9 million compared to $56.6 million in Q4 2024. As Barron noted, excluding $14.3 million of high-volume COVID GMP clean cap sales in the prior year quarter, revenue increased 18% year-over-year.”
2025-06-30–present
Biotechnology · Healthcare
CFO
2025-06-30–present
